Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBI-992 in advanced solid tumors
NCT06480240Phase 2Active, not recruiting
- Sponsor
- OBI Pharma
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
A Phase 2 trial of BSI-04702 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer (GC), sponsored by OBI Pharma. Started Jun 2024; status: active, not recruiting.
02
Drugs
BSI-04702
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT06480240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06480240.